The main function of the 3′–5′ DNA exonuclease TREX1 is to digest cytosolic single-stranded DNA to prevent activation of cell-intrinsic responses to immunostimulatory DNA. TREX1 translocates to the nucleus following DNA damage with its nuclear activities being less well defined. Although mutations in human TREX1 have been linked to autoimmune/inflammatory diseases, the mechanisms contributing to the pathogenesis of these diseases remain incompletely understood. Here, using mass spectrometry and co-immunoprecipitation assays and in vivo overexpression models, we show that TREX1 interacts with poly(ADP-ribose) polymerase-1 (PARP1), a nuclear enzyme involved in the DNA damage response. Two zinc finger domains at the amino terminus of PARP1 were required for the interaction with TREX1 that occurs after nuclear translocation of TREX1 in response to DNA damage. Functional studies suggested that TREX1 may contribute to stabilization of PARP1 levels in the DNA damage response and its activity. These results provide new insights into the mechanisms of single-stranded DNA repair following DNA damage and alterations induced by gene mutations.

Recognition of nucleic acids by innate immune receptors, exemplified by Toll-like receptors 3, 7/8, and 9, plays an important role in the clearance of viral infections. However, if self-nucleic acids are involved, recognition can also contribute to the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), by driving inappropriate activation of type I interferon (IFN1) through an innate immune signaling pathway (1, 2).

TREX1, the most abundant 3′–5′ DNA exonuclease in mammalian cells, specifically cleaves single-stranded DNA (ssDNA) or mispaired 3′ termini of DNA duplexes (3, 4). Mutations in the human TREX1 gene have been linked to four clinically overlapping autoimmune/inflammatory diseases: Aicardi-Goutières syndrome (AGS), familial chilblain lupus, SLE, and retinal vasculopathy with cerebral leukodystrophy (RVCL). These diseases exhibit both genetic and clinical overlaps but present as distinct clinical conditions (5). AGS, a lethal early onset disease characterized by an inflammatory encephalopathy and elevated levels of IFN1 in the cerebrospinal fluid, has been associated primarily with autosomal recessive mutations in TREX1 that impair its exonuclease activity (6). Patients with RVCL, caused by distinct dominant mutations in TREX1, present as adults with retinal and cerebral endotheliopathy together with cerebral leukodystrophy. A subset of these patients develops systemic vascular involvement manifested by Raynaud phenomenon or hepatic or renal dysfunction (7). All the TREX1 mutations described in RVCL cause C-terminal frameshifts that result in deletion of the predicted transmembrane domain responsible for its anchoring in the endoplasmic reticulum but leave enzymatic function intact. Familial chilblain lupus, an inherited cutaneous form of SLE caused by dominant mutations in TREX1, is not associated with neurological manifestations, but there is some overlap with AGS as some AGS patients develop chilblains and autoantibodies (8, 9). Dominant mutations in TREX1 have also been identified in 0.5–2% of SLE patients (10, 11).

*This work was supported, in whole or in part, by the National Institutes of Health Intramural Research Program of the NIAID.
1 Both authors contributed equally to this work.
2 Present address: Dept. of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004 Japan.
3 To whom correspondence should be addressed: Virology and Cellular Immunology Section, Laboratory of Immunogenetics, NIAID, National Institutes of Health, Rockville, Maryland 20852 and 4Stem Cell Project Group, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506 Japan.

The 3′–5′ DNA Exonuclease TREX1 Directly Interacts with Poly(ADP-ribose) Polymerase-1 (PARP1) during the DNA Damage Response*

Received for publication, January 2, 2014, and in revised form, September 30, 2014. Published, JBC Papers in Press, October 2, 2014, DOI 10.1074/jbc.M114.547331

Takuya Miyazaki1,2, Yong-Soo Kim3, Jeongheon Yoon3, Hongsheng Wang4, Teruhiko Suzuki5, and Herbert C. Morse III1,2

From the 1,2Virology and Cellular Immunology Section, Laboratory of Immunogenetics, NIAID, National Institutes of Health, Rockville, Maryland 20852 and 3Stem Cell Project Group, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506 Japan

Background: TREX1 is a 3′−5′ DNA exonuclease, and mutations in human TREX1 are associated with autoimmune/inflammatory diseases.

Results: TREX1 interacts with poly(ADP-ribose) polymerase-1 (PARP1).

Conclusion: TREX1 contributes to maintenance of suitable PARP1 levels and its functions in the DNA damage response.

Significance: Identification of the molecular mechanism of TREX1 is necessary for understanding the development or progression of TREX1-associated diseases.
Studies have shown that Trex1 knock-out mice die from a severe inflammatory cardiomyopathy with elevated expression of IFN1 and production of autoantibodies (12, 13). Cytosolic ssDNA fragments derived from endogenous retroelements (13) or aberrant replication intermediates (14) accumulate in TREX1-deficient cells of the knock-out mice, leading to the activation of autoimmune immunity through the IFN signaling pathway. Similar ssDNA fragments were identified in TREX1-deficient cells derived from a patient with AGS (14). Taken together, the studies of deficient mice provide a mechanistic link between accumulation of self-nucleic acids and induction of an IFN response and autoimmunity. However, because the mice do not exhibit pathologies that resemble the major manifestations characteristic of patients with AGS (encephalopathy) or RVCL (retinal and cerebral endotheliopathy), the mechanisms contributing to the pathogenesis of these human diseases remain incompletely understood.

Several roles for TREX1 have been identified in various cellular processes. First, TREX1 is a component of the SET complex that normally resides in the endoplasmic reticulum (15). This complex, including TREX1, translocates to the nucleus during granzyme A-mediated activation of apoptosis. In the nucleus, TREX1 removes ssDNA nicks linked by the SET complex endonuclease, NM23-H1, to inhibit rejoining of the nicked ends (15, 16). In fact, cells carrying the familial chilblain lupus-associated TREX1 mutation, D18N, are relatively resistant to granzyme A, suggesting the importance of TREX1 to granzyme A-activated DNA damage (17). Second, it was also found that following relocalization caused by DNA damage TREX1 is associated with replication foci and attenuates chronic activation of the ataxia telangiectasia mutated-dependent DNA damage response (14). These observations are indicative of roles for TREX1 in the nucleus, the details of which remain to be clearly defined. Interestingly, TREX1 and other genes found to be mutated among patients with AGS have been shown to affect the human immunodeficiency virus (HIV) in various stages of its intracellular replication cycle. TREX1 helps HIV evade innate immune recognition by degrading cytosolic ssDNA generated during reverse transcription (18). Thus, TREX1 has distinct function in both the nucleus and the cytoplasm.

The purpose of the current study was to clarify the underlying mechanisms by which TREX1 contributes to the development of autoimmune/inflammatory diseases. We hypothesized that as-yet-unknown proteins may interact with TREX1 and that these interactions may be affected by disease-causing mutations in the gene. Here, we identified a novel TREX1 binding partner, poly(ADP-ribose) polymerase-1 (PARP1), a nuclear enzyme that participates in the DNA damage response (19, 20). Although PARP1 is involved in many aspects of the cellular responses to DNA damage, it is essential for repair of ssDNA breaks predominantly through base excision repair (BER) mechanisms. We demonstrate that TREX1 translocates to the nucleus in response to DNA damage and interacts there with nuclear PARP1. Our findings suggest that TREX1 may have a previously unappreciated role in the DNA damage response and that mutation-induced alterations in TREX1 function could contribute to development or progression of human autoimmune/inflammatory diseases.

**EXPERIMENTAL PROCEDURES**

**Cell Culture Conditions**—Human embryonic kidney (HEK) 293, HeLa, and K562 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in DMEM (Quality Biological, Gaithersburg, MD) supplemented with 10% fetal bovine serum (Quality Biological), 50 μM 2-mercaptoethanol (Invitrogen), and penicillin-streptomycin under 5% CO₂ in air at 37 °C. To induce DNA damage, cells were treated with 2 mM sodium arsenite (Sigma-Aldrich) and 5 mM hydroxyurea (Sigma-Aldrich) for the indicated times.

**Antibodies**—Rabbit polyclonal anti-TREX1 antibody was kindly provided by Dr. Parul Kothari and Dr. John Atkinson (Washington University School of Medicine, St. Louis, MO). Other antibodies used in this study included antibodies to GFP and V5 (Invitrogen); those to PARP1, cleaved PARP1, GAPDH, and calreticulin; mouse monoclonal antibody to rabbit IgG (conformation-specific); and HRP-conjugated anti-mouse IgG antibody (Cell Signaling Technology, Danvers, MA); anti-lamin A/C antibody, HRP-conjugated anti-rabbit IgG antibody, and HRP-conjugated anti-goat IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA); those to FLAG, p53, and α-tubulin (Sigma-Aldrich); anti-histone H3 antibody (Millipore, Billerica, MA); and anti-poly(ADP-ribose) (PAR) antibody (Trevenig, Gaithersburg, MD).

**DNA Constructs**—To generate intensely fluorescent protein N-terminal portion (IFPN)-tagged TREX1 vectors (21), wild-type TREX1 coding regions were directionally subcloned into the IFPN protein complementation vector (VYF101 vector) kindly provided by Dr. Zhiyong Ding (University of Texas M. D. Anderson Cancer Center, Houston, TX). Briefly, the TREX1 coding sequence was amplified with forward primer (ATCGATATGCGTCAGGCTGTGTGTTGCG with Clal site in italics) and reverse primer (GAATTCATTCTTCCTGGCTTGTTGCC with EcoRI site in italics), and the Clal/EcoRI PCR fragment was subcloned into the Clal/EcoRI-digested VYF101 vector. To generate FLAG-tagged TREX1 vectors, the coding region for TREX1 was subcloned into pCMV-3Tag-6 vector (Agilent Technologies, Santa Clara, CA). To generate V5-tagged PARP1 and its serial deletion mutant constructs (N1, N2, N3, N4, C1, C2, and C3), cDNA sequences corresponding to different regions were amplified by PCR and subcloned into pcDNA3.1/V5-His-TOPO vector (Invitrogen).

**Stable Cell Lines**—To generate stable cell lines expressing wild-type TREX1, HEK293 Tet-On cells (Clontech) were transfected with each construct in IFPN-tagged plasmids (in VYF101 vector). The cells were selected with 200 μg/ml Zeocin (Invitrogen) for at least 2 weeks, and the expression level of TREX1 was determined by Western blotting using anti-TREX1 or anti-GFP antibody.

**Preparation of Cell Extracts and Co-immunoprecipitation**—Whole cell lysates were prepared in Nonidet P-40 cell lysis buffer (50 mM Tris, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM Na₃VO₄, 1% Nonidet P40, 0.02% NaN₃) (Invitrogen) supplemented with protease inhibitor (Roche Applied Science), or nuclear and cytoplasmic extracts were prepared according to the manufacturer’s protocol for the NE-PER nuclear and cytoplasmic extraction kit or for the subcellular protein fraction-
TREX1 Interaction with PARP1

ation kit (Thermo Scientific, Rockford, IL). For co-immunoprecipitation (co-IP) assays, protein G-coupled magnetic beads (Dynabeads Protein G, Invitrogen) were used according to the manufacturer’s protocol. Briefly, 50 μl of magnetic beads were washed with PBS/Tween 20 and incubated with a primary antibody for 1 h at 4 °C. After washing the bead-antibody complex, cell lysates were cross-linked to the complex and incubated overnight at 4 °C. The bead-antibody-antigen complex was washed with PBS/Tween 20 three times and eluted in 20 μl of premixed NuPAGE lithium dodecyl sulfate sample buffer and NuPAGE sample reducing agent (Invitrogen) and incubated for 10 min at 70 °C. Samples were loaded onto a gel for SDS-PAGE followed by Western blotting.

Western Blotting—Protein expression levels were determined by SDS-PAGE and subsequent immunoblotting as described previously (22). Briefly, 20–30 μg of protein determined by the BCA protein assay method (Thermo Scientific) was separated on a NuPAGE Novex 4–12% Bis-Tris gel (Invitrogen) and transferred to a polyvinylidene difluoride membrane. After blocking with a 5% skim milk solution, the blot was incubated with a primary antibody according to the manufacturer’s recommended dilution in the blocking solution containing 0.1% Tween 20. The antibody was detected with an HRP-conjugated secondary antibody, developed using an enhanced chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific), and exposed to film. When co-IP followed by Western blotting was performed, an anti-rabbit IgG conformation-specific antibody was used as a bridging antibody before incubation with an anti-mouse IgG-HRP antibody to minimize the denatured and reduced rabbit IgG light or heavy chains.

Mass Spectrometry and Protein Identification—Extracts from TREX1 stably transfected cell lines were immunoprecipitated with anti-GFP antibody, and the bead-antibody-antigen complexes were eluted and loaded onto a gel for SDS-PAGE. The gel was stained with Coomassie Brilliant Blue, and protein bands were dissected. Mass spectrometry for protein identification was performed by the Research Technologies Branch of National Institute of Allergy and Infectious Diseases, National Institutes of Health. Briefly, the gel slices containing protein bands were subjected to in-gel trypsin digestion. The released peptides and 50% acetonitrile extractions from in-gel digestion were dried by SpeedVac (Labconco, Kansas, MO). The recovered peptides were resuspended in 5 μl of solvent A (0.1% formic acid, 2% acetonitrile, 97.9% water). The bound peptides were separated at 500 nl/min using an AQ C18 reverse phase medium (3-μm particle size and 200-μm pore) packed in a 150-mm length) from Precision Capillary Columns (Thermo Scientific) and transferred to a polyvinylidene difluoride membrane. After blocking with a 5% skim milk solution, the blot was incubated with a primary antibody according to the manufacturer’s recommended dilution in the blocking solution containing 0.1% Tween 20. The antibody was detected with an HRP-conjugated secondary antibody, developed using an enhanced chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific), and exposed to film. When co-IP followed by Western blotting was performed, an anti-rabbit IgG conformation-specific antibody was used as a bridging antibody before incubation with an anti-mouse IgG-HRP antibody to minimize the denatured and reduced rabbit IgG light or heavy chains.

DNA Fragmentation Assay—Cells were lysed in 100 μl of lysis buffer (100 mM NaCl, 1 mM Tris-Cl, pH 8.0, 1 mM EDTA, pH 8.0, 0.1% SDS, 0.1 mg/ml Proteinase K) and incubated at 50 °C for 3 h followed by addition of 5 μl of SDS-OUT reagent (Thermo Scientific). The content was mixed and incubated on ice for 20 min followed by centrifugation at 10,000 g for 10 min at 4 °C. Supernatants were collected in fresh centrifuge tubes and treated with RNase for 20 min on ice followed by quantification using a Nanodrop spectrophotometer (Thermo Scientific). Equal amounts of DNA (1.5 μg) were electrophoresed in a 2% agarose gel. Images of DNA agarose gels were captured using Multimfit™ Light Cabinet (Alpha Innotech Corp., San Leandro, CA). Densitometric analysis of the fragmented DNA was done using ImageJ software by subtracting the high molecular weight DNA density from total DNA density.

Recombinant Protein Expression and Purification—Escherichia coli strain BL21 harboring a pET-15b construct expressing human PARP1 proteins was grown in LB broth supplemented with ampicillin at 37 °C and induced with 1 mM isopropyl 1-thio-β-D-galactopyranoside. Bacterial cells expressing His-tagged proteins were suspended with lysis buffer and lysed by sonication. Soluble His6-tagged proteins were separated from insoluble cell debris by centrifugation at 14,000 rpm and purified by affinity chromatography on nickel-nitrilotriacetic acid-agarose beads (Thermo Scientific). For expression of GST fusion proteins, cDNAs for human TREX1 were subcloned into pGEX-4T-3 (GE Healthcare). GST-TREX1 was expressed in E. coli strain BL21. Cells were lysed in lysis buffer supplemented with a mixture of protease inhibitors, and the proteins were purified with glutathione-Sepharose 4B (GE Healthcare) according to the standard protocol.

GST Pulldown Assay—Pulldown experiments were performed with purified recombinant proteins. Briefly, GST-tagged recombinant proteins were incubated with glutathione-Sepharose 4B beads for 4 h at 4 °C. Beads were then washed thoroughly with PBS five times and added to the His-tagged protein followed by incubation overnight at 4 °C. After washing, bound proteins were analyzed by SDS-PAGE and immunoblotting using anti-PARP antibody. GST-TREX1 was analyzed by SDS-PAGE and Coomassie Brilliant Blue staining.

Transfections with Plasmids and siRNAs—Cells were transfected with the plasmids or TREX1 siRNAs using Lipofectamine LTX or RNAiMAX (Invitrogen), respectively. The TREX1 siRNA was designed by Santa Cruz Biotechnology as a pool of three target-specific siRNAs of 20–25 nucleotides. A scrambled non-targeting siRNA (Santa Cruz Biotechnology) was used as a negative control.

Cell Proliferation Assay—siRNA-treated HeLa cells were incubated in 96-well plates for 48 h and assayed by 4-[3-(2-methoxy-4-nitrophenyl)-2-[4-nitrophenyl]-2H-5-tetrazolio]-1,3-benzenedisulphonate sodium salt (WST-8) using Cell Counting Kit-8 (Sigma-Aldrich). Absorbance at 450 nm was
measured for each culture using an ELISA plate reader (SpectraMax, Molecular Devices, Sunnyvale, CA).

Measurement of PARP1 Activity—PARP1 activity in cell extracts was analyzed using the HT colorimetric PARP/apoptosis assay (Trevigen) based on the ELISA method, which semi-quantitatively detects PAR deposited onto histone proteins in a 96-well format. Briefly, 100-ng protein lysates prepared from siRNA-transfected cells in triplicate were incubated with 2 mM nicotine adenine dinucleotide (NAD) and activated DNA in the histone-coated plate and developed with an anti-PAR monoclonal antibody, an anti-mouse IgG-HRP antibody, and a TACS-Sapphire colorimetric substrate. The reaction was read at 450 nm using an ELISA plate reader.

Statistical Analysis—Data are reported as the mean ± S.E. The paired t test was used to test for differences. p values < 0.05 were considered to be statistically significant.

RESULTS
Identification of PARP1 as a Novel Protein Partner for TREX1—To identify TREX1-interacting proteins, we first generated stable cell lines expressing human TREX1 protein in HEK293 cells. We confirmed that the expression levels of IFPN-tagged TREX1 were higher than that of endogenous TREX1 and that the IFPN-tagged TREX1 protein could be detected by Western blotting with anti-GFP antibody (Fig. 1A).

TREX1 Interaction with PARP1

FIGURE 1. Identification of PARP1 as a novel protein partner for TREX1. A, expression levels of both IFPN-tagged TREX1 and endogenous TREX1 proteins from HEK293 stable cell lines expressing TREX1 were determined by Western blotting. α-Tubulin served as an endogenous loading control. B, IFPN-tagged TREX1 was purified with anti-GFP antibody from the cell extracts, eluted in SDS buffer, and subjected to SDS-PAGE. The proteins were visualized by Coomassie Brilliant Blue (CBB) staining. Peptide sequences of the PARP1 protein were obtained by mass spectrometry. Two of seven peptide sequences that identified PARP1 are shown. Note that the IFPN-TREX1 target protein of size 50 kDa is almost overlapped by the heavy chain IgG band. HC, heavy chain; LC, light chain. C, the whole-cell extracts from the stable cell lines were immunoprecipitated with anti-GFP antibody and immunoblotted with anti-PARP1 or anti-TREX1 antibody. Protein input was assessed by Western blotting with the indicated antibodies. D, purified PARP1 was incubated with GST or GST-TREX1 coupled to glutathione-Sepharose 4B. Proteins retained on Sepharose were eluted and then blotted with the indicated antibodies.
motif, and a C-terminal catalytic domain (19). A third ZF domain (ZF3), which has recently been characterized, is distinct in structure and function from ZF1 and ZF2 (23). To identify the domains of PARP1 that interact with TREX1, we generated a V5-tagged full-length PARP1 and a panel of deletion mutants (Fig. 2A). These constructs were co-transfected with FLAG-tagged TREX1 followed by co-IP with anti-V5 antibody and Western blotting with anti-FLAG antibody and vice versa (Fig. 2B). We confirmed that full-length PARP1 interacted with TREX1 (Fig. 2B, lane Wild type) but not with empty vector (lane Mock). Furthermore, we found that TREX1 interacted with PARP1 domains included in N1, N2, N3, and N4 (lanes N1–N4) but not with domains included in C1, C2, and C3 (lanes C1–C3, gray rectangles). These results indicate that only ZF1 and ZF2 are required for binding. A possible contribution from the recently described ZF3 was not examined and thus cannot be ruled out.

**DNA Damage Induces Nuclear Translocation of TREX1**—
TREX1 is localized to endoplasmic reticulum through its C-terminal transmembrane region (24), and previous reports have shown that TREX1 translocates to the nucleus following DNA damage induced by UV or γ-irradiation, hydroxyurea, or granzyme A (14, 15, 25). We hypothesized that nuclear translocation of TREX1 is required for interaction with nuclear PARP1 following DNA damage. To test this hypothesis, we first examined subcellular localization of TREX1 following induction of DNA damage. K562 cells were treated with sodium arsenite and hydroxyurea, which rapidly induce DNA breaks (26), and cell extracts recovered at various times after treatment were used to generate cytoplasmic and nuclear fractions. Western blotting showed that TREX1 was normally localized to cytoplasm and that the expression of nuclear TREX1 increased following treatment with arsenite (Fig. 3A) and hydroxyurea (Fig. 3B) in a time-dependent manner. The lower panel in Fig. 3A shows that nuclear TREX1 increased within 15 min and reached maximum levels at 60 min, suggesting that this translocation is rapid, but when compared with cytoplasmic levels, only a small amount of TREX1 translocated to the nucleus. TREX1 expression in cells treated with hydroxyurea was also increased about 3-fold at 240 min compared with the control level (Fig. 3B). We then proceeded to fractionate cell extracts into different cellular compartments, including cytoplasmic, cytoplasmic membrane, soluble nuclear, and chromatin-bound fractions using HeLa cells either untreated or treated with arsenite for 60 min. Western blotting and the analyses of band intensities showed that the levels of TREX1 clearly increased in both the soluble nuclear and chromatin-bound fractions following arsenite treatment and that the levels of PARP1 increased in chromatin-bound fractions but not in nuclear fractions (Fig. 3C). These results demonstrate that following DNA damage TREX1 translocated to the nucleus, especially to chromatin, in concert with PARP1, suggesting that TREX1 is associated with the DNA damage response by PARP1.

**Endogenous TREX1 Interacts with PARP1 in Response to DNA Damage**—To examine the physiological interaction between TREX1 and PARP1, we performed co-IP using endogenous proteins of HeLa cells treated with arsenite to induce DNA damage. PARP1 was detected in TREX1 immunoprecipitates of whole-cell extracts from arsenite-treated cells but not in the TREX1 immunoprecipitates of cells cultured under normal conditions or in immunoprecipitates with a control IgG

---

**FIGURE 2. Identification of PARP1 domains required for interaction with TREX1.** A, V5-tagged full-length PARP1 and deletion mutants used in this study are schematically represented. Numbers denote amino acid residues. **BRCT**, breast cancer 1 protein (BRCA1) C terminus domain; **WGR**, tryptophan-glycine-arginine domain; **REG**, regulatory domain; **CAT**, catalytic domain. B, cell extracts from HEK293 cells expressing V5-tagged full-length or deletion mutants of PARP1 with FLAG-TREX1 were immunoprecipitated with anti-V5 antibody followed by Western blotting with anti-FLAG antibody or vice versa. Arrows show specific protein identification. NS, nonspecific band; HC, heavy chain; LC, light chain.
The interaction was not affected by pretreatment with DNase I (Fig. 4B), demonstrating that TREX1 interacts with PARP1 independently of interactions with DNA. We also confirmed this interaction using nuclear extracts (Fig. 4C). Next, we examined the effect of arsenite treatment on the binding capacity of TREX1 to PARP1 over time (Fig. 4D) because nuclear translocation of TREX1 would likely be associated with PARP1 interactions as predicted from the results in Fig. 3. We found that interactions of the proteins increased significantly in the nucleus following DNA damage (Fig. 4D), suggesting that TREX1 may act to modulate the function of PARP1 in the nucleus. These data suggest that the DNA damage is necessary for TREX1 and PARP1 to interact under physiologic conditions. It is worth noting that direct binding was seen in cells without intentional DNA damage in the TREX1 overexpression models shown in Figs. 1 and 2. It may be that the high levels of TREX1 expressed in these cells enabled detection of the interaction even in cells with minimal DNA damage.

Knockdown of TREX1 Promotes PARP1 Cleavage and Loss of PARP1 Enzymatic Activity—To understand the physiological effects of TREX1 on PARP1 function, we examined cells treated with a TREX1-specific siRNA. We found that the knockdown effect of TREX1 by siRNA was specific for the target molecule and was greater at 48 than 24 h (Fig. 5A). Studies of cell proliferation using a WST-8 assay showed that the TREX1 knockdown resulted in significantly reduced cell expansion (Fig. 5B). This result is consistent with data from an earlier study that showed that cells from Trex1 knock-out mice were retarded in G1/S transition and proliferated more slowly, resulting in a prolonged cell doubling time (14). This difference in cell numbers in our study could be due to an inhibition of cell cycle progression or cell death, raising the possibility that TREX1 may normally be associated with cell cycle control or inhibition of cell death. To probe these possibilities, we examined the effect of TREX1 knockdown on levels of p53, PARP1, and cleaved PARP1 proteins by Western blotting (Fig. 5C). The results...
showed that levels of p53, a classic indicator of DNA damage (27), were significantly increased and that the knockdown of TREX1 was associated with reduced levels of PARP1 and increased levels of cleaved PARP1. Previous studies showed that PARP1 is cleaved at the same site by caspase-3 or granzyme B to yield an N-terminal DNA-binding domain and a C-terminal catalytic domain, resulting in PARP1 inactivation (28). We confirmed this by using a DNA fragmentation assay. Total genomic DNA was isolated from HeLa cells after 48 h of transfection with TREX1-specific siRNA or control siRNA. These data suggest that reduction of TREX1 levels was quite separate from its interactions with PARP1.

**DISCUSSION**

Previous studies have identified both nuclear and cytoplasmic activities of TREX1. As an interacting component of the endoplasmic reticulum-resident SET complex, TREX1 translocates to the nucleus of cells to degrade nicked DNA during granzyme A-mediated cell death (15) or following exposure to genotoxic stress. Normal nuclear functions may include excision of mispaired DNA 3’ termini (29) and BER. Cytoplasmic activities, such as digestion of cytosolic HIV DNA (18) and enhancement of lysosomal biogenesis (30), have recently been identified. Proteins that partner with TREX1 to mediate these functions are reasonably well known for some activities (15) but not at all for others. Identification of partnering proteins involved in both nuclear and cytoplasmic activities of TREX1 is likely to be of importance for understanding the pathogenesis of differing human diseases caused by distinct mutations in TREX1: inflammatory/autoimmune disorders, including AGS (6), SLE (10, 11), and familial chilblain lupus (8, 9), and the endotheliopathy RVCL (7). This study, undertaken to detect potential additional interacting proteins, identified PARP1 as a previously unappreciated partner for TREX1. The results of this study demonstrated that TREX1 interacts with PARP1 after nuclear translocation of the TREX1 in response to...
DNA damage and that nuclear TREX1 may contribute to the regulation of PARP1 activity in the DNA damage response. Previous studies showed that these proteins play important roles in response to DNA damage, including ssDNA break repair. We confirmed the interaction using mass spectrometry and co-IP methods using in vivo overexpression models and in vitro; however, the physiological interaction was identified only under conditions involving DNA damage.

We found that the two N-terminal ZF domains of PARP1, ZF1 and ZF2, were critical for its interaction with TREX1. The fact that this interaction was not dependent on the presence of DNA is indicative of a direct interaction between the proteins rather than one based on the ability of both to bind DNA. An earlier study showed that PARP1 recognizes nicked DNA by utilizing the ZF motifs in its DNA-binding domain. However, these regions can also mediate protein-protein interactions as they contain sequences responsible for interactions between ZF1 and ZF2 (31). Furthermore, the ZFs can also act as an interface with various protein partners, including the BER pathway protein XRCC1 (32, 33). A number of other PARP1 partner proteins have been identified, including BIN1 (34), SIRT6 (35), and IκB kinase, protein inhibitor of activated STAT protein γ, and ataxia telangiectasia mutated (36), although the PARP1 domains required for these interactions have not been carefully

**FIGURE 5. Knockdown of TREX1 promotes PARP1 cleavage and loss of PARP1 enzymatic activity.** A, HeLa cells were transfected with TREX1-specific or control siRNAs at the indicated concentrations (10–100 nM) and time course (24 or 48 h). Expression levels of endogenous TREX1 proteins were determined by Western blotting. α-Tubulin served as an endogenous loading control. (-), no siRNA treatment. B, cell proliferation assessed by the tetrazolium method was used with TREX1-specific or control siRNA-treated cells (50 nM). The cells were incubated for the indicated times (24–72 h), and the absorbance was measured for each culture using an ELISA plate reader (n = 3). Data are given as the mean ± S.E. (error bars). *, p < 0.01 by paired t test. C, HeLa cells were transfected with TREX1-specific or control siRNA (50 nM) for 48 h, and the expression levels of the indicated proteins were determined by Western blotting (n = 4). Densitometric analyses of the blots are shown in the lower panel, and values are given as the mean ± S.E. (error bars) for TREX1, p53, PARP1, and cleaved PARP1 levels relative to GAPDH levels from the four independent experiments. *, p < 0.05; **, p < 0.005; ***, p < 0.0005 by paired t test. (-), no siRNA treatment. D, agarose gel electrophoresis of genomic DNA isolated from cells transfected with TREX1 and control siRNA for 48 h. The intensity of fragmented DNA in the lower panel was calculated, and mean with S.D. (error bars) was plotted. The p value was calculated by comparing with the control sample using paired t test. AU, arbitrary units. E, HeLa cells were transfected with TREX1-specific or control siRNA (50 nM) for 48 h, and PARP1 activity in cell extracts (100 ng of protein) was measured by quantification of PAR from histones attached to strip wells in a 96-well format using the HT colorimetric PARP/apoptosis assay kit (n = 3). Data are given as the mean ± S.E. (error bars). *, p < 0.05; **, p < 0.005; ***, p < 0.0005 by paired t test. (-), no siRNA treatment. n.s., not significant.
mapped. It is possible that the ZF-dependent interaction between TREX1 and PARP1 could interfere with or augment the ability of PARP1 to engage in these interactions.

The main function of TREX1 is to digest ssDNA derived from endogenous retroelements or from processing of aberrant replication intermediates to prevent their accumulation and activation of cell-intrinsic responses to immunostimulatory DNA (13, 14). However, the physiological function of nuclear TREX1 remained unclear. It was shown previously that TREX1 translocates to the nucleus following DNA damage induced by UV or γ-irradiation, hydroxyurea (14, 25), granzyme A (15), the environmental carcinogen benzo(a)pyrene (25), or the DNA topoisomerase I inhibitor camptothecin (37). Chowdhury et al. (15) showed that TREX1 works as a proofreading exonuclease for BER because TREX1 degrades DNA in concert with endonuclease NM23-H1 during granzyme A-mediated cell death, indicating that TREX1 acts in the nucleus and may function in DNA repair. Our results show that TREX1 translocated to the nucleus of K562 and HeLa cells after treatment with arsenite. The new finding from the current study is the association of TREX1 with PARP1 following nuclear translocation. Although PARP1 is involved in many aspects of the cellular response to DNA damage, it plays a key role in BER of ssDNA break (19, 20).

In conclusion, this study has identified and characterized an interaction between TREX1 and PARP1 during DNA damage response. TREX1 is associated with stabilization of PARP1 levels and transcription with PARP1 (38). These reports support the hypothesis that TREX1 may be a component of a chromatin-bound protein complex that also includes SET and PARP1.

We also examined the functional role of TREX1 in the regulation of PARP1 stability and function and found that knock-down of TREX1 reduced cell expansion in association with a loss of PARP1 enzymatic activity. This finding was dependent on the induction of PARP1 cleavage and an increase in p53 levels, directly linking TREX1-PARP1 interactions to the DNA damage response (39). Furthermore, we found that cells with increasing levels of transfected TREX1 exhibited progressively increased PARP1 stability and that TREX1 stimulated increased autopoly(ADP-ribosyl)ation of PARP1 following DNA damage. Although nuclear translocation of TREX1 seems to be essential for PARP1 stabilization in the DNA damage response, the exact molecular mechanisms of its regulation of PARP1 are only partially understood. It remains to be determined how TREX1 is associated with stabilization of PARP1 or how the TREX1-PARP1 complex is targeted to DNA nicks. It will also be important to determine whether the TREX1-PARP1 interaction is affected by mutations responsible for the various TREX1-related diseases.

In conclusion, this study has identified and characterized an interaction between TREX1 and PARP1 in response to DNA damage in vivo and in vitro. Functional studies suggested that TREX1 is associated with stabilization of PARP1 levels and function. At present, we are not able to distinguish between the possibility that the effects we see on apoptosis associated with depletion and overexpression of TREX1 might be due to anti-apoptotic effects of TREX1 itself or that the binding of TREX1 to PARP1 may be important to the regulation of PARP1 in the
DNA damage response. Further studies are necessary to determine whether this partnering is important to the development or progression of TREX1-associated diseases.

Acknowledgments—We thank Parul Kothari and John Atkinson (Washington University School of Medicine) for providing specific antibodies and plasmids and detailed responses to our queries, Farokh Dotiwalla and Judy Lieberman (Harvard Medical School) for helpful advice related to this work, Robert Crouch (National Institute of Child Health and Human Development) for critical reading of antibodies and plasmids and detailed responses to our queries, or progression of TREX1-associated diseases.

Further studies are necessary to determine whether this partnering is important to the development or progression of TREX1-associated diseases.

REFERENCES

1. Barbalat, R., Ewald, S. E., Mouchess, M. L., and Barton, G. M. (2011) Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185–214
2. Barber, G. N. (2011) Innate immune DNA sensing pathways: STING, AIM2 and the regulation of interferon production and inflammatory responses. Curr. Opin. Immunol. 23, 10–20
3. Höss, M., Robins, P., Naven, T. J., Pappin, D. J., Spichor, J., and Lindahl, T. (1999) A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J. 18, 3868–3875
4. Mazur, D. J., and Perrino, F. W. (1999) Identification and expression of the exocellular DNA exonuclease TREX1 and TREX2 cDNA sequences encoding mammalian 3'-5' exonucleases. J. Biol. Chem. 274, 19655–19660
5. Kavanagh, D., Spitzer, D., Kothari, P. H., Shaikh, A., Liszewski, M. K., Richards, A., and Atkinson, J. P. (2008) New roles for the major human 3'-5' exo- nuclease TREX1 in human disease. Cell Cycle 7, 1718–1725
6. Crow, Y. J., Hayward, B. E., Parmar, R., Robins, P., Harvey, S., Hollis, T., Gahr, M., Perrino, F. W., and Lieberman, J. (2006) The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell 23, 133–142
7. Richards, A., van den Maagdenberg, A. M., Jen, J. C., Kavanagh, D., Berdelle, N., and Kaina, B. (2007) Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome. Nat. Genet. 39, 917–920
8. Lee-Kirsch, M. A., Chowdhury, D., Harvey, S., Gong, M., Schulz, H., Rüschendorf, F., Stein, A., Pfef- fner, F. W., and Hubner, N. (2007) A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531–537
9. Yan, N., Regalado-Magdos, A. D., Stigellbou, B., Lee-Kirsch, M. A., and Lieberman, J. (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11, 1005–1013
10. Long, R., Xue, X., Zhang, Y., Zhang, D., Sun, S., and Demple, B., Perrino, F. W., and Lieberman, J. (2003) Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 112, 659–672
11. Le-Kirsch, M. A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engle, K., Pfeiffer, C., Hollis, T., Gahr, M., Perrino, F. W., Lieberman, J., and Hubner, N. (2007) A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531–537
12. Ding, Z., Liang, J., Lu, Y., Yu, Q., Songyang, Z., Lin, S. Y., and Mills, G. B. (2006) A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc. Natl. Acad. Sci. U.S.A. 103, 15014–15019
13. Lee, C. H., Melchers, M., Wang, H., Torrey, T. A., Slota, R., Qi, C. F., Kim, J. Y., Lugar, P., Kong, H. J., Farrington, L., van der Zouwen, B., Zhou, J. X., Ruiz, L., Lloberas, J., Macias, M. J., Fita, I., and Celada, A. (2007) Structure of the dimeric exonuclease TREX1 in complex with DNA displays a pro- tease domain. Cell 131, 873–886
14. Gibson, B. A., and Kraus, W. L. (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13, 411–424
15. Christmann, M., Tomicic, M. T., Aasland, D., Berdelle, N., and Kaina, B. (2006) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13, 411–424
16. Yang, Y. G., Lindahl, T., and Barnes, D. E. (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmunity. Cell 131, 873–886
17. Chowdhury, D., Beresford, P. J., Zhu, P., Zhang, D., Sun, S. J., Demple, B., Perrino, F. W., and Lieberman, J. (2006) The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell 23, 133–142
18. Fan, Z., Beresford, P. I., Oh, D. Y., Zhang, D., and Lieberman, J. (2003) Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 112, 659–672
19. Lee-Kirsch, M. A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engle, K., Pfeiffer, C., Hollis, T., Gahr, M., Perrino, F. W., Lieberman, J., and Hubner, N. (2007) A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531–537
20. Lee-Kirsch, M. A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engle, K., Pfeiffer, C., Hollis, T., Gahr, M., Perrino, F. W., Lieberman, J., and Hubner, N. (2007) A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531–537
21. Lee, C. H., Melchers, M., Wang, H., Torrey, T. A., Slota, R., Qi, C. F., Kim, J. Y., Lugar, P., Kong, H. J., Farrington, L., van der Zouwen, B., Zhou, J. X., Lougaris, V., Lipsky, P. E., Grammer, A. C., and Morse, H. C., 3rd (2006) Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J. Exp. Med. 205, 63–72
22. Langelier, M. F., Planck, J. L., Roy, S., and Pascal, J. M. (2012) Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336, 728–732
23. Brucet, M., Querol-Audí, J., Serra, M., Ramírez-Esparza, X., Bertlik, K., Ruiz, L., Lloberas, J., Macias, M. J., Fita, I., and Celada, A. (2007) Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW Domains. J. Biol. Chem. 282, 14547–14557
24. Christmann, M., Tomicic, M. T., Aasland, D., Berdelle, N., and Kaina, B. (2010) Three prime exonuclease I (TREX1) is a Fox/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo[a]pyrene-induced DNA damage. Nucleic Acids Res. 38, 6418–6432
25. Yang, Y. G., Lindahl, T., and Barnes, D. E. (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmunity. Cell 131, 873–886
26. Yang, Y. G., Lindahl, T., and Barnes, D. E. (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmunity. Cell 131, 873–886
27. Yang, Y. G., Lindahl, T., and Barnes, D. E. (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmunity. Cell 131, 873–886
28. Yang, Y. G., Lindahl, T., and Barnes, D. E. (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmunity. Cell 131, 873–886
29. Yang, Y. G., Lindahl, T., and Barnes, D. E. (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmunity. Cell 131, 873–886
genotoxic carcinogens: p53 induction as an indicator of genotoxic damage. *Carcinogenesis* **19**, 1117–1125

28. Zhu, P., Martinvalet, D., Chowdhury, D., Zhang, D., Schlesinger, A., and Lieberman, J. (2009) The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5’-diphosphate-ribose) polymerase-1. *Blood* **114**, 1205–1216

29. Mazur, D. J., and Perrino, F. W. (2001) Excision of 3’ termini by the Trex1 and TREX2 3’→5’ exonucleases. Characterization of the recombinant proteins. *J. Biol. Chem.* **276**, 17022–17029

30. Hasan, M., Koch, J., Rakheja, D., Pattnaik, A. K., Brugarolas, J., Dozmorov, I., Levine, B., Wakeland, E. K., Lee-Kirsch, M. A., and Yan, N. (2013) Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. *Nat. Immunol.* **14**, 61–71

31. Ali, A. A., Timinszky, G., Arribas-Bosacoma, R., Kozlowski, M., Hassa, P. O., Hassler, M., Ladurner, A. G., Pearl, L. H., and Oliver, A. W. (2012) The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. *Nat. Struct. Mol. Biol.* **19**, 685–692

32. Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-de Murcia, J., and de Murcia, G. (1998) XRCCI1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. *Mol. Cell. Biol.* **18**, 3563–3571

33. Shall, S., and de Murcia, G. (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? *Mutat. Res.* **460**, 1–15

34. Pyndiah, S., Tanida, S., Ahmed, K. M., Cassimere, E. K., Choe, C., and Sakamuro, D. (2011) c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. *Sci. Signal.* **4**, ra19

35. Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., Vaidya, A., Seluanov, A., and Gorbunova, V. (2011) SIRT6 promotes DNA repair under stress by activating PARP1. *Science* **332**, 1443–1446

36. Stilmann, M., Hinz, M., Arslan, S. C., Zimmer, A., Schreiber, V., and Scheidereit, C. (2009) A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IκB kinase activation. *Mol. Cell* **36**, 365–378

37. Wang, C. J., Lam, W., Bussem, S., Chang, H. M., and Cheng, Y. C. (2009) TREX1 acts in degrading damaged DNA from drug-treated tumor cells. *DNA Repair* **8**, 1179–1189

38. Gamble, M. J., and Fisher, R. P. (2007) SET and PARP1 remove DEK from chromatin to permit access by the transcriptions machinery. *Nat. Struct. Mol. Biol.* **14**, 548–555

39. Kanai, M., Hanashiro, K., Kim, S. H., Hanai, S., Boulares, A. H., Miwa, M., and Fukasawa, K. (2007) Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribsylation). *Nat. Cell Biol.* **9**, 1175–1183